Best For Recommendations# Maximum Weight Loss# Recommendation : Retatrutide Reason : Phase 3 TRIUMPH-4 showed 28.7% weight loss at 68 weeks, substantially exceeding CagriSema's 20.4% at 68 weeks
Semaglutide activates only GLP-1 receptors, while tirzepatide (a GLP-1/GIP receptor agonist) engages dual pathways, often producing faster or more substantial weight lossup to 22% in clinical trials versus 15% for semaglutide alone
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen should be used cautiously, particularly if you are dehydrated or have kidney concerns, cardiovascular risk factors, or gastrointestinal conditions
For instance, semaglutide for diabetes (Ozempic) typically starts at 0.25 mg weekly, increasing monthly until reaching the maintenance dose of 1 mg or 2 mg weekly
GHK-Cu works through copper delivery and gene modulation
Trials including TRIUMPH-4 and TRANSCEND-T2D-1 have concluded